⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22380610 | 0.78 | — | — | |
| SCHEMBL9985512 | 0.77 | L3MBTL1 (0.62) | — | |
| SCHEMBL9986002 | 0.77 | L3MBTL1 (0.79) | — | |
| SCHEMBL14403837 | 0.75 | L3MBTL1 (0.43) | — | |
| SCHEMBL16290202 | 0.74 | — | — | |
| SCHEMBL17574527 | 0.74 | — | — | |
| SCHEMBL1097687 | 0.72 | — | — | |
| SCHEMBL14042845 | 0.72 | — | — | |
| SCHEMBL3114690 | 0.72 | — | — | |
| SCHEMBL3591445 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2022-06-16 | — | — | US | claimed |
| CN-114173772-A | Inhibitors of CD40-CD154 binding | 托尼克斯医药控股公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3952853-A1 | INHIBITORS OF CD40-CD154 BINDING | Tonix Pharmaceuticals Holding Corp. (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210831-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2020-10-15 | — | — | WO | claimed |
| WO-2014002110-A1 | SUBSTITUTUED PYRAZOLE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF. | RALLIS INDIA LIMITED (IN) | 2014-01-03 | — | — | WO | claimed |
| WO-2014002109-A1 | SUBSTITUTED TETRAZOLE COMPOUNDS AND PROCESS THEREOF | RALLIS INDIA LIMITED (IN) | 2014-01-03 | — | — | WO | claimed |
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| US-12410210-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250154194-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-12264177-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12252509-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240343756-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-20240336648-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005048922-A2 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2003065987-A2 | GRANZYME B INHIBITORS | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |